Sunitinib: In advanced, well differentiated pancreatic neuroendocrine tumors

BioDrugs

Volumn 25, Issue 5, 2011, Pages 307-316

  Deeks, Emma D ^a   Raymond, Eric ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b BEAUJON HOSPITAL   (France)

Author keywords

Adis Drug Profiles; Pancreatic cancer; Sunitinib

Indexed keywords

CARBAMAZEPINE; CD135 ANTIGEN; CLARITHROMYCIN; COLONY STIMULATING FACTOR 1; CYTOCHROME P450; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; STEM CELL FACTOR RECEPTOR; SU012662; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER GRADING; CANCER GROWTH; CREATININE CLEARANCE; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; GRAPEFRUIT JUICE; HAIR DISCOLORATION; HALF LIFE TIME; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATITIS; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 80053264509     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11207360-000000000-00000     Document Type: Review

References (40)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008 Jun 20; 26 (18): 3063-72
2. Dimou AT, Syrigos KN, Saif MW. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP 2010 Mar 5; 11 (2): 135-8
3. Asa SL. Pancreatic endocrine tumors. Mod Pathol 2011 Apr; 24 Suppl. 2: S66-77
4. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines. Well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010 Aug; 39 (6): 735-52
5. Ehehalt F, Saeger HD, Schmidt CM, et al. Neuroendocrine tumors of the pancreas. Oncologist 2009 May; 14 (5): 456-67
6. Alsamarai S, Libutti SK, Saif MW. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010 Jul 5; 11 (4): 336-40
7. Raymond E, Faivre S, Hammel P, et al. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol 2009 Dec; 4 (4): 253-4
8. Grande E, Dièz JJ, Pachón V, et al. Advances in the therapy of gastroenteropancreatic- neuroendocrine tumours (GEP-NETs). Clin Transl Oncol 2010 Jul; 12 (7): 481-92
9. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from welldifferentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression.Mod Pathol 2003 Jul; 16 (7): 652-9 (Pubitemid 36871497)
10. Fjällskog MLH, Lejonklou MH, Öberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003 Apr; 9 (4): 1469-73 (Pubitemid 36418403)
11. Pfizer Inc. Sutent- (sunitinib malate) capsules, oral: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021938s13s17s18lbl.pdf [Accessed 2011 Aug 10]
12. Pfizer Ltd. Sutent 12.5, 25, 37.5 and 50mg hard capsules: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/0006 87/WC500057737.pdf [Accessed 2011 Aug 10]
13. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009 Jul; 45 (11): 1959-68
14. Escudier B, Roigas J,Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokinerefractory metastatic renal cell carcinoma. J Clin Oncol 2009 Sep 1; 27 (25): 4068-75
15. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009 Jun 20; 27 (18): 3027-35
16. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010 Nov 1; 16 (21): 5260-8
17. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 Jan 1; 24 (1): 25-35 (Pubitemid 46630490)
18. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003 Jan; 9 (1): 327-37 (Pubitemid 36109749)
19. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and plateletderived growth factor receptor b in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003 May; 2 (5): 471-8
20. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003 May 1; 101 (9): 3597-605 (Pubitemid 36857948)
21. Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7 (3): 225-33
22. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005 Feb 10; 23 (5): 939-52 (Pubitemid 46202314)
23. European Medicines Agency. Sutent: scientific discussion [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Scientific-Discussion/human/000687/WC500057733.pdf [Accessed 2011 Aug 11]
24. Center for Drug Evaluation and Research. Approval package for sunitinib: pharmacology review(s) [online]. Available from URL: http://www.access data.fda.gov/drugsatfda-docs/nda/2006/021938-S000-Sutent-PharmR.pdf [Accessed 2011 Aug 11]
25. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.NEngl J Med 2011 Feb 10; 364 (6): 501-13
26. Etienne-Grimaldi M, Reneè N, Scotté F, et al. Pharmacokinetics (PK) of sunitinib and its metabolite in patients with castrated refractory prostate cancer (CRPC) enrolled in the French multicenter PROSUT phase II study [abstract no. 124P]. Ann Oncol 2010 Oct; 21 Suppl. 8: viii54
27. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009 Nov 3; 101 (9): 1543-8
28. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008 Mar; 61 (3): 515-24 (Pubitemid 350275988)
29. Gangadhar TC, Cohen EEW, Wu K, et al. Two drug interaction studies of sirolimus in combinationwith sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res 2011 Apr 1; 17 (7): 1956-63
30. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006 Mar; 17 (3): 353-8
31. Bello CL, Garrett M, Sherman L, et al. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol 2010 Sep; 66 (4): 699-707
32. Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of unitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010 Apr; 50 (4): 472-81
33. Houk BE, Bello CL, Kang D, et al. A population pharmacokinetic metaanalysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009 Apr 1; 15 (7): 2497-506
34. Shukla S, Robey RW, Bates SE, et al. Sunitinib (Sutent, SU11248), a smallmolecule receptor tyrosine kinase inhibitor, blocks function of the ATPbinding cassette (ABC) transporters p-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009 Feb; 37 (2): 359-65
35. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008 Jul 10; 26 (20): 3403-10
36. Pfizer. A continuation study using sunitinib malate for patients leaving treatment on a previous sunitinib study [ClinicalTrials.gov identifier NCT00428220]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Mar 8]
37. Pfizer. A treatment protocol for patients continuing from a prior SU011248 protocol [ClinicalTrials.gov identifier NCT00443534]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 Mar 8]
38. Van Cutsem E, Seitz JF, Raoul J, et al. Evaluation of progression-free survival by blinded independent central review in patients with progressive, welldifferentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo [abstract no. 249]. J Clin Oncol 2011 Feb 1; 29 (4 Suppl.)
39. Raymond E, Niccoli P, Raoul J, et al. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (pts) with advanced unresectable pancreatic neuroendocrine tumors (NET) [abstract no. 4008]. J Clin Oncol 2011 May 20; 29 (15 Suppl.)
40. Ishak J, Valle J, Van Cutsem E, et al. Overall survival analysis of sunitinib after adjustment for crossover in patients with pancreatic neuroendocrine tumors [poster]. 8th Annual European Neuroendocrine Tumor Society Conference; 2011 Mar 9-11; Lisbon, Portugal